Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site

Open access
Rippin, Ido, Khazanov, Netaly, Ben Joseph, Shirley, Kudinov, Tania, Berent, Eva, Arciniegas Ruiz, Sara Melisa, Marciano, Daniele, Levy, Laura, Gruzman, Arie, Senderowitz, Hanoch, Eldar-Finkelman, Hagit · 2020 · International Journal of Molecular Sciences

Abstract

The serine/threonine kinase, GSK-3, is a promising drug discovery target for treating multiple pathological disorders. Most GSK-3 inhibitors that were developed function as ATP competitive inhibitors, with typical limitations in specificity, safety and drug-induced resistance. In contrast, substrate competitive inhibitors (SCIs), are considered highly selective, and more suitable for clinical practice. The development of SCIs has been largely neglected in the past because the ambiguous, undefined nature of the substrate-binding site makes them difficult to design. In this study, we used our previously described structural models of GSK-3 bound to SCI peptides, to design a pharmacophore model and to virtually screen the “drug-like” Zinc database (~6.3 million compounds). We identified leading hits that interact with critical binding elements in the GSK-3 substrate binding site and are chemically distinct from known GSK-3 inhibitors. Accordingly, novel GSK-3 SCI compounds were designed and synthesized with IC50 values of~1–4 μM. Biological activity of the SCI compound was confirmed in cells and in primary neurons that showed increased β-catenin levels and reduced tau phosphorylation in response to compound treatment. We have generated a new type of small molecule GSK-3 inhibitors and propose to use this strategy to further develop SCIs for other protein kinases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21228709

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Design of a pharmacophore model based on GSK-3β binding model with substrate competitive inhibitor (SCI) peptide (A) Structural model of GSK-3β bound to our previously described SCI peptide L803F. The primed. phosphate S10(p) in the peptide interacts with the phosphate-binding pocket (Arg 96, Arg 180, Ly 205, marked blue), Phe12, at the C-terminal end of the peptide, interacts with Phe93 located in the “89–95” loop (orange), Ala3 in the peptide interacts with pTyr216, and Pro5 in the peptide interacts with Val 214 and Ile217, all residues that form the “hydrophobic patch” (beige). The P-loop including Phe67 is in green, the ATP molecule and Mg+2 (cyan balls) are shown. (B) The pharmacophore model is composed of two hydrogen bond acceptor features (F1, F2: red vectors), one anionic feature (F3: red porcupine shape), and three hydrophobic features (F4, F5, F6: yellow spheres). Excluded volumes were placed in positions that are sterically claimed by the protein environment. GSK-3 interacting residues are marked.
Figure 1 Design of a pharmacophore model based on GSK-3β binding model with substrate competitive inhibitor (SCI) peptide (A) Structural model of GSK-3β bound to our previously described SCI peptide L803F. The primed. phosphate S10(p) in the peptide interacts with the phosphate-binding pocket (Arg 96, Arg 180, Ly 205, marked blue), Phe12, at the C-terminal end of the peptide, interacts with Phe93 located in the “89–95” loop (orange), Ala3 in the peptide interacts with pTyr216, and Pro5 in the peptide interacts with Val 214 and Ile217, all residues that form the “hydrophobic patch” (beige). The P-loop including Phe67 is in green, the ATP molecule and Mg+2 (cyan balls) are shown. (B) The pharmacophore model is composed of two hydrogen bond acceptor features (F1, F2: red vectors), one anionic feature (F3: red porcupine shape), and three hydrophobic features (F4, F5, F6: yellow spheres). Excluded volumes were placed in positions that are sterically claimed by the protein environment. GSK-3 interacting residues are marked.CC BY · PubMed Central
Figure 2 Discovery of GSK-3 SCI hits. (A) In vitro GSK-3β kinase assays were conducted with selected hits identified in the three iterative virtual screening cycles. Structure of compounds is summarized in Tables S1–S3. Ctrl represents GSK-3 activity no compounds (100%). Results are mean of three independent experiments ± SEM using one-way ANOVA with Dunnett’s post hoc test. ** p < 0.01 *** p < 0.001. The anthracene core used in the third search cycle is illustrated at the top right panel. The SCI peptide L807mts (L807) was used as a reference in the 3rd cycle assays. (B) Chemical structures of selected best hits of each cycle. The anthracenone–isoxazole core is highlighted in compound 2-1. (C) IC50 values of selected best hits.
Figure 2 Discovery of GSK-3 SCI hits. (A) In vitro GSK-3β kinase assays were conducted with selected hits identified in the three iterative virtual screening cycles. Structure of compounds is summarized in Tables S1–S3. Ctrl represents GSK-3 activity no compounds (100%). Results are mean of three independent experiments ± SEM using one-way ANOVA with Dunnett’s post hoc test. ** p < 0.01 *** p < 0.001. The anthracene core used in the third search cycle is illustrated at the top right panel. The SCI peptide L807mts (L807) was used as a reference in the 3rd cycle assays. (B) Chemical structures of selected best hits of each cycle. The anthracenone–isoxazole core is highlighted in compound 2-1. (C) IC50 values of selected best hits.CC BY · PubMed Central
Figure 3 GSK-3 SCI compounds interact with the kinase substrate binding site and are chemically unique. (A) Docking models of compounds 3-7 and 3-8 with GSK-3β. Key interacting GSK-3β residues are highlighted, and detailed interactions are summarized in Table 1. The carboxylic acid moiety form salt bridges and H-bonding with the GSK-3-phosphate-binding pocket, Arg 96, Arg 180, Lys 205, and with Val 214. The anthracenone–isoxazole core forms π–π stacking interactions with Phe 93. Interactions were analyzed by the Maestro software. (B) In vitro kinase assays were performed with GSK-3β (WT) or with the F93A mutant in the presence of indicated compounds, L803F (20 μM each), and SB216763 (1 μM). Results are mean of three independent experiments ± SEM analyzed by one way ANOVA with Dunnett’s multiple comparisons. ** p < 0.01 with inhibitor vs no inhibitor (C) Principal component analysis (PCA) analysis of all compounds discovered through the three search cycles together with representative GSK-3-ATP competitive inhibitors (listed in Table S4). The first and second PCs accounted for 81.8% and 7.7% of the original variance and are shown at the X- and Y-axis respectively. Black circles represent the ATP competitive inhibitors, colored circles represent compounds from cycle 1 (green), 2 (red) and 3 (blue). Circles with yellow dots represent compounds 2-1, 3-7 and 3-8.
Figure 3 GSK-3 SCI compounds interact with the kinase substrate binding site and are chemically unique. (A) Docking models of compounds 3-7 and 3-8 with GSK-3β. Key interacting GSK-3β residues are highlighted, and detailed interactions are summarized in Table 1. The carboxylic acid moiety form salt bridges and H-bonding with the GSK-3-phosphate-binding pocket, Arg 96, Arg 180, Lys 205, and with Val 214. The anthracenone–isoxazole core forms π–π stacking interactions with Phe 93. Interactions were analyzed by the Maestro software. (B) In vitro kinase assays were performed with GSK-3β (WT) or with the F93A mutant in the presence of indicated compounds, L803F (20 μM each), and SB216763 (1 μM). Results are mean of three independent experiments ± SEM analyzed by one way ANOVA with Dunnett’s multiple comparisons. ** p < 0.01 with inhibitor vs no inhibitor (C) Principal component analysis (PCA) analysis of all compounds discovered through the three search cycles together with representative GSK-3-ATP competitive inhibitors (listed in Table S4). The first and second PCs accounted for 81.8% and 7.7% of the original variance and are shown at the X- and Y-axis respectively. Black circles represent the ATP competitive inhibitors, colored circles represent compounds from cycle 1 (green), 2 (red) and 3 (blue). Circles with yellow dots represent compounds 2-1, 3-7 and 3-8.CC BY · PubMed Central
Figure 4 Newly designed GSK-3 SCI molecules. (A) Structures of new molecules 4-1 to 4-5. (B) In vitro GSK-3β kinase assays were conducted with new compounds and 3-8 (20 μM each). Results show the percentage of GSK-3β activity without inhibitor (100%) and represent the mean of three independent experiments ± SEM analyzed by one way ANOVA with Dunnett’s multiple comparisons. **** p < 0.0001. (C) Dose–response curves of GSK-3β inhibition of new compounds and as compared to 3-8. Results are mean of three independent experiments ± SEM. For 4-3 and 4-4 * p < 0.05 for all concentrations, for the rest of the molecules, * p < 0.05 at concentrations ≥ 5 μM as determined by one way ANOVA with Dunnett’s multiple comparisons, new compounds vs. 3-8. (D) PCA analysis of new compounds 4-1 to 4-5 together with GSK-3-ATP competitive inhibitors (listed in Table S4). The first and second PCs accounted for 81.8% and 7.7% of the original variance and are shown at the X- and Y-axis respectively. Black circles represent the ATP competitive inhibitors, red circles represent new compounds.
Figure 4 Newly designed GSK-3 SCI molecules. (A) Structures of new molecules 4-1 to 4-5. (B) In vitro GSK-3β kinase assays were conducted with new compounds and 3-8 (20 μM each). Results show the percentage of GSK-3β activity without inhibitor (100%) and represent the mean of three independent experiments ± SEM analyzed by one way ANOVA with Dunnett’s multiple comparisons. **** p < 0.0001. (C) Dose–response curves of GSK-3β inhibition of new compounds and as compared to 3-8. Results are mean of three independent experiments ± SEM. For 4-3 and 4-4 * p < 0.05 for all concentrations, for the rest of the molecules, * p < 0.05 at concentrations ≥ 5 μM as determined by one way ANOVA with Dunnett’s multiple comparisons, new compounds vs. 3-8. (D) PCA analysis of new compounds 4-1 to 4-5 together with GSK-3-ATP competitive inhibitors (listed in Table S4). The first and second PCs accounted for 81.8% and 7.7% of the original variance and are shown at the X- and Y-axis respectively. Black circles represent the ATP competitive inhibitors, red circles represent new compounds.CC BY · PubMed Central
Figure 5 Docking new GSK-3 SCI molecules in GSK-3 substrate binding site. Docking models of GSK-3β bound to 4-2, 4-3 and 4-4. Detailed interactions are also summarized in Table 2. Like 3-8 and the other leading hits, the new molecules interacted with the GSK-3 phosphate-binding pocket, Phe 93 and Val 214. 4-3 and 4-4 showed additional interactions with Phe 67, Ly 85 (4-3), or, Ser 66 (4-4). Interactions were analyzed by the Maestro software.
Figure 5 Docking new GSK-3 SCI molecules in GSK-3 substrate binding site. Docking models of GSK-3β bound to 4-2, 4-3 and 4-4. Detailed interactions are also summarized in Table 2. Like 3-8 and the other leading hits, the new molecules interacted with the GSK-3 phosphate-binding pocket, Phe 93 and Val 214. 4-3 and 4-4 showed additional interactions with Phe 67, Ly 85 (4-3), or, Ser 66 (4-4). Interactions were analyzed by the Maestro software.CC BY · PubMed Central
Figure 6 Kinetic analysis of new compounds. (A) Michaelis Menten plots of ATP competitive assays with 4-3 and 4-4. The corresponding Lineaver–Burk plots are shown at the right panel. (B) Michaelis Menten plots of substrate competitive assays with 4-3 and 4-4. The corresponding Lineaver–Burk plots are shown at the right panel. (C) In vitro kinase assays of F93A mutant in the presence of 4-1 through 4-5 (20 μM each). Results are mean of three independent experiments ± SEM using one-way ANOVA with Dunnett’s post hoc test. (D) GSK-3α kinase assays were performed with 4-1 through 4-5 (20 μM each). Results the mean of three independent experiments ± SEM using one-way ANOVA with Dunnett’s post hoc test. **** p < 0.0001 treated vs. control. (E) GSK-3β kinase assays were performed with 4-3 and 4-4 (20 μM) in the presence of 0.05% Triton × 100. (F) Kinase assays were performed with a representative repertoire of protein kinases in the presence of 4-4 (10 μM). Inhibition by 4-4 is presented as a percentage of kinase activity in the control assay with no inhibitor. Results are means ± SD of two independent experiments performed in duplicates. GSK-3α/β are marked red.
Figure 6 Kinetic analysis of new compounds. (A) Michaelis Menten plots of ATP competitive assays with 4-3 and 4-4. The corresponding Lineaver–Burk plots are shown at the right panel. (B) Michaelis Menten plots of substrate competitive assays with 4-3 and 4-4. The corresponding Lineaver–Burk plots are shown at the right panel. (C) In vitro kinase assays of F93A mutant in the presence of 4-1 through 4-5 (20 μM each). Results are mean of three independent experiments ± SEM using one-way ANOVA with Dunnett’s post hoc test. (D) GSK-3α kinase assays were performed with 4-1 through 4-5 (20 μM each). Results the mean of three independent experiments ± SEM using one-way ANOVA with Dunnett’s post hoc test. **** p < 0.0001 treated vs. control. (E) GSK-3β kinase assays were performed with 4-3 and 4-4 (20 μM) in the presence of 0.05% Triton × 100. (F) Kinase assays were performed with a representative repertoire of protein kinases in the presence of 4-4 (10 μM). Inhibition by 4-4 is presented as a percentage of kinase activity in the control assay with no inhibitor. Results are means ± SD of two independent experiments performed in duplicates. GSK-3α/β are marked red.CC BY · PubMed Central
Figure 7 Biological activity of 4-4. (A) SH-SY5Y cells were treated with 4-4 for 4 h and levels of cytoplasmic β-catenin were determined by immunoblot analysis. Densitometry analysis is shown on the lower panel. Results are mean of three independent experiments ± SEM * p < 0.05 by one-way ANOVA with Dunnett’s post hoc test (B) Hippocampal mouse neurons were treated with 4-4 (5 μM), or CHIR99021 (CHIR, 10 μM) for 4 h. Cells were co-stained with anti-β-catenin and anti-MAP2 antibodies. Images show overlapping β-catenin (green) and MAP2 (red) staining along with respective split channels (shown in grey). The β-catenin signal was evaluated by Image J Colocalization-finder plugin. Results present the mean of 60 cells ± SEM, ** p < 0.01, *** p < 0.0001 by one-way ANOVA with Dunnett’s post hoc test. NT- non treated. (C) Hippocampal mouse neurons were treated with 4-4 (20 μM) for 4 h. Levels of phosphorylated tau (Ser 396), tau, and β-actin were determined by immunoblot analysis. Bar graph represents densitometry analysis of ptau/βactin and results are mean of three independent experiments ± SEM using Student’s t-test. * p < 0.05. For all panels, Ctrl or 0 concentration represents cells treated with vehicle (DMSO/1%Tween 80 at matched dilutions—1:2000–4000).
Figure 7 Biological activity of 4-4. (A) SH-SY5Y cells were treated with 4-4 for 4 h and levels of cytoplasmic β-catenin were determined by immunoblot analysis. Densitometry analysis is shown on the lower panel. Results are mean of three independent experiments ± SEM * p < 0.05 by one-way ANOVA with Dunnett’s post hoc test (B) Hippocampal mouse neurons were treated with 4-4 (5 μM), or CHIR99021 (CHIR, 10 μM) for 4 h. Cells were co-stained with anti-β-catenin and anti-MAP2 antibodies. Images show overlapping β-catenin (green) and MAP2 (red) staining along with respective split channels (shown in grey). The β-catenin signal was evaluated by Image J Colocalization-finder plugin. Results present the mean of 60 cells ± SEM, ** p < 0.01, *** p < 0.0001 by one-way ANOVA with Dunnett’s post hoc test. NT- non treated. (C) Hippocampal mouse neurons were treated with 4-4 (20 μM) for 4 h. Levels of phosphorylated tau (Ser 396), tau, and β-actin were determined by immunoblot analysis. Bar graph represents densitometry analysis of ptau/βactin and results are mean of three independent experiments ± SEM using Student’s t-test. * p < 0.05. For all panels, Ctrl or 0 concentration represents cells treated with vehicle (DMSO/1%Tween 80 at matched dilutions—1:2000–4000).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 58 references

Cited by

See all 30

Metadata

Authors
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., & Eldar-Finkelman, H.
Affiliations
  • Tel Aviv University (IL)
  • Bar-Ilan University (IL)
  • Department of Human Molecular Genetics &amp; Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
  • Israel Institute for Biological Research (IL)
Corresponding author
Eldar-Finkelman, Hagit
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-11-18
Volume
21
Issue
22
Pages
8709
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3104987635
Cited by
25
References
58
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 7
FWCI
2.11
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Israel Science Foundatio (1843/17)
  • Israel Innovation Authority (4632)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
glycogen synthase kinase-3, substrate binding site, small-molecule kinase inhibitors, pharmacophore model, virtual screening, β-catenin, tau phosphorylation, protein kinase inhibitors, drug resistance
MeSH terms
Protein Domains, Animals, Binding Sites, Cells, Cultured, Humans, Kinetics, Mice, Inbred C57BL, Protein Binding, Substrate Specificity, Drug Design, Molecular Structure, Glycogen Synthase Kinase 3, Cell Line, Tumor, Protein Kinase Inhibitors, Small Molecule Libraries, Drug Discovery, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. https://app.cochat.ai/papers/10.3390/ijms21228709
The paper
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., & Eldar-Finkelman, H. (2020). Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21228709

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.